K

Kidswell Bio Corporation
TSE:4584

Watchlist Manager
Kidswell Bio Corporation
TSE:4584
Watchlist
Price: 302 JPY 9.03% Market Closed
Market Cap: ¥15B

Operating Margin

7.7%
Current
Improving
by 34.3%
vs 3-y average of -26.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
7.7%
=
Operating Income
¥505.7m
/
Revenue
¥6.6B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
7.7%
=
Operating Income
¥505.7m
/
Revenue
¥6.6B

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Kidswell Bio Corporation
TSE:4584
15B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in Japan
Percentile
54th
Based on 6 730 companies
54th percentile
7.7%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Kidswell Bio Corporation
Glance View

Market Cap
15B JPY
Industry
Biotechnology

Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Intrinsic Value
584.5 JPY
Undervaluation 48%
Intrinsic Value
Price
K
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
7.7%
=
Operating Income
¥505.7m
/
Revenue
¥6.6B
What is Kidswell Bio Corporation's current Operating Margin?

The current Operating Margin for Kidswell Bio Corporation is 7.7%, which is above its 3-year median of -26.6%.

How has Operating Margin changed over time?

Over the last 3 years, Kidswell Bio Corporation’s Operating Margin has increased from -23.5% to 7.7%. During this period, it reached a low of -57.2% on Sep 30, 2023 and a high of 7.7% on Oct 30, 2025.

Back to Top